References
- Gulland A. How “Brexit” might affect the pharmaceutical industry. BMJ 2016;353:i2615
- Impact of Brexit on cancer care and research. Lancet Oncol 2016;17:539
- Brexit and junior doctors’ contracts: the real threat to the NHS. Lancet 2016;388:211
- The Queen on the application of (1) Gina Miller & (2) Deir Tozetti Dos Santos v Secretary of State for Exiting the European Union [2016] EWHC 2768
- Article 35 of the Charter of Fundamental Rights of the European Union
- Looking beyond Brexit: union without Union. Lancet Infectious Diseases 2016;16:1203
- May T. Brexit speech at the Conservative Convention. 2 October 2016. Available at: www.independent.co.uk/news/uk/politics/theresa-may-conference-speech-article-50-brexit-eu-a7341926.html [Last accessed 16 January 2017]
- Managed Access Agreement - Elosulfase alfa for treating mucopolysaccharidosis type IVa. Available at: https://www.nice.org.uk/guidance/hst2/resources/managed-access-agreement-december-2015-2238935869 [Last accessed 16 January 2017]
- Ward A. Pharmaceuticals: value over volume. Financial Times. 24 September 2015. Available at: www.ft.com/content/0a1fec32-629b-11e5-9846-de406ccb37f2 [Last accessed 16 January 2017]
- Available at: www.accesstomedicineindex.org [Last accessed 16 January 2017]
- Horton R. Offline: the meanings of Brexit. Lancet 2016;388:14
- Picavet E, Annemans L, Cleemput I, et al. Market uptake of orphan drugs – a European analysis. J Clin Pharm Ther 2012;37:6647